C4 Therapeutics

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

AT&T Inc. (T)

News

Price Target

Markets

Analyst Ratings

Trading Ideas

BIRK

BKNG

CCCC

AT&amp;T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday

movers image

MEOH

MERC

Methanex, Merck And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Movers

Pre-Market Outlook

AUMN

BENF

BMRA

BURU

EAST

FEMY

Intelligent Bio Solutions Inc. - Common Stock

INBS

LIFW

MULN

SMMT

SVRA

TNXP

WHLR

Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

C4 Therapeutics Inc

Press Releases

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

Health Care

General

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

Management

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Earnings

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

ABBV

IMGN

PRTC

Alector

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Atossa Therapeutics

Coherus BioSciences

Coya Therapeutics

Editas Medicine

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Fate Therapeutics

Genelux

HilleVax

Immunic

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lexeo Therapeutics

Macrogenics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

RAPT Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Vigil Neuroscience

Vaxart

Exagen

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Wells Fargo

Stephens & Co.

BMO Capital

Stifel

Morgan Stanley

Comments

C4 Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell